No Data
No Data
Intraday quick overview | The three major indices rose sharply, the Keji Index rose more than 2%, Bilibili rose nearly 8%, and JD and Meituan rose more than 5%
Biotech stocks rose, with Yao Ming Biotech up more than 6%, Genting Xinyao by more than 5%, Kingsray Biotech by more than 4%, and BeiGene Shenzhou by nearly 2%; Apple concept stocks generally rose, Ruisheng Technology and Gaowei Electronics by about 5%, and Shunyu Optics and Qiutai Technology by about 2%.
CARsgen Announced 2023 Annual Results
SHANGHAI, March 27, 2024 /PRNewswire/ -- March 27, 2024, CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematol
Keji Pharmaceutical Announces 2023 Annual Results
SHANGHAI, March 27, 2024 /PRNewswire/ -- Keji Pharmaceutical (stock code: 2171.HK), an innovative CAR-T cell therapy company focused on treating hematologic malignancies and solid tumors, announced its 2023 results. Performance highlights at a glance, Saikaize (Zewokie Orense injection, CT053) new drug marketing application approved by the State Drug Administration CT041 received IND approval from the State Drug Administration for adjuvant treatment of pancreatic cancer with positive Claudin18.2 expression CT011 obtained from the State Drug Administration
Can the first commercial CAR-T product, which lost money in three years after launch, become a “lifesaver” for Keji Pharmaceutical? |Annual Report Interpretation
① Keji Pharmaceutical has been in a state of loss since its launch. Compared with 2022, the loss margin was relatively narrow in 2023. ② At the end of last year, the company's stock price was hit hard twice in a short period of time. ③ In March of this year, the company's first CAR-T product, Sikaize, was approved for sale. Keji Pharmaceutical expects the peak annual terminal sales of this product to reach more than 1 billion yuan.
Keji Pharmaceutical-B (02171) announced annual results. Losses attributable to shareholders of 748 million yuan narrowed 16.19% year-on-year
According to the Zhitong Finance App, Keji Pharmaceutical-B (02171) announced the results for the year ended December 31, 2023. The group achieved R&D expenditure of 662 million yuan (RMB, same below) during the period, a year-on-year decrease of 2.74%; losses attributable to shareholders amounted to 748 million yuan, a year-on-year decrease of 16.19%; and a basic loss of 1.34 yuan per share. According to the announcement, the main reason for the narrowing was the reduction in share-based remuneration, which totaled 14 million yuan for the year ended December 31, 2023, a decrease of 30 million yuan compared to 44 million yuan for the year ended December 31, 2022; R&D
CARSGEN-B: ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2023
No Data